Immunomedics initiated with a Buy at B. Riley FBR. B. Riley FBR analyst Madhu Kumar started Immunomedics with a Buy rating and $53 price target and added the shares to his firm’s Alpha Generator list. The company has the makings of a blockbuster cancer drug, Kumar tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.